We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Oncothyreon's financial performance into perspective.
Nov 16, 2009 Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
Nov 11, 2009 Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
View all releases »
There are currently no Events & Presentations scheduled.
return to top ^
